The largest segment of the market, antibiotic drugs, is projected to grow at a CAGR of 5.9% to reach $50 billion in 2014. Its value is estimated at $37.6 billion in 2009.
Bacterial vaccines, the other segment of the market, is estimated at $3.9 billion in 2009, and is expected to increase at a 5-year CAGR of 31.6% to reach $15.5 billion in 2014.
Antibiotic resistance is a major health crisis throughout the world that requires an intensely focused action plan. Although resistance cannot be prevented, the problem is exacerbated by the fact that the pipeline targeting it is very lean, as the field was neglected by the industry for a long time.
The antibiotics sector is witnessing a new wave of interest in terms of investment, which is leading to innovation that was absent for more than two decades. The bacterial vaccines sector is expected to show particularly commendable growth trends during the 2009-2014 forecast period.
Regulatory trends emerging in various markets are expected to play key roles in the market growth. Because the best way to contain the resistance problem is to restrict the use of these products, it is expected to have a negative effect on the sector’s market growth. This is especially true for the established antibiotic classes that are facing serious resistance issues. Thus, the use of new classes of antibiotics will be encouraged, which will drive market growth.
This report is valuable reading for investors, policy makers, and industry participants.
Analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs.
Posts
No comments:
Post a Comment